表紙
市場調査レポート

Inovio Pharmaceuticals, Inc.:パイプライン製品の分析

Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 224584
出版日 ページ情報 英文 73 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
Inovio Pharmaceuticals, Inc.:パイプライン製品の分析 Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日: 2016年07月13日 ページ情報: 英文 73 Pages
概要

Inovio Pharmaceuticals, Inc.では、がんや各種感染症の治療・予防用ワクチンの開発に従事しています。同社が開発したSynConワクチンは、既存/新規の菌株の病原体(インフルエンザなど)に対して、汎用性の高い免疫反応を示しています。同社の治験プログラムの中には、白血病・C型肝炎・子宮頚部異形成向けの第II相治験や、HIV・インフルエンザ向けの第I相治験などが含まれています。

当レポートでは、米国のバイオ医薬品企業、Inovio Pharmaceuticals, Inc.(Inovio)における医薬品の研究開発の進捗状況について分析し、同社の製品パイプラインの構造や、治験の全体的な進捗状況、主要なパイプライン製品のプロファイルと開発状況、同社のプロファイルと最新動向などを調査しております。

目次

Inovio Pharmaceuticals, Inc.:現状

  • 企業概要
  • 主要情報
  • 主要データ

研究開発(R&D)の概況

  • 主な治療領域

パイプライン・レビュー

  • 開発段階別のパイプライン製品
  • パイプライン製品:単剤治療薬
  • パイプライン製品:併用治療モダリティ
  • パイプライン製品:パートナー製品
    • パートナー製品/併用治療モダリティ
  • パイプライン製品:アウトライセンス製品
    • アウトライセンス製品/併用治療モダリティ

パイプライン製品の概要

  • 治験段階のパイプライン製品
    • 第II相製品/併用治療モダリティ
    • 第I相製品/併用治療モダリティ
  • 初期段階のパイプライン製品
    • 治験前製品/併用治療モダリティ

薬剤のプロファイル

  • VGX-3100
    • 製品の概要
    • 作用機序
    • 研究開発(R&D)の進展
  • Syncon H1N1インフルエンザ向けユニバーサル・ワクチン
  • INO-3112
  • INO-3401
  • INO-3510
  • INO-3605
  • INO-3609
  • INO-8000
  • PENNVAX-B
  • Pennvax-G
  • VGX-1027
  • VGX-3400X
  • VRC-01
  • チクングニヤ熱向けDNAワクチン
  • H3N2インフルエンザ向けDNAワクチン
  • H7N9インフルエンザ向けユニバーサルDNAワクチン
  • MERSコロナウイルス感染症向けDNAワクチン
  • 天然痘向けDNAワクチン
  • DNAベースIL-33+HPV-16 DNAワクチン
  • INO-1400
  • INO-7103
  • INO-7105
  • MAV-12
  • Pennvax-GP
  • エボラ熱・マールブルクフィロウイルス向け多価DNAワクチン

パイプラインの分析

  • 標的別
  • 投与方法別
  • 分子の種類別
  • 作用機序別

パイプライン製品の最新動向

開発が休止状態の製品

開発が中止された製品

  • 開発が中止された製品のプロファイル
    • ミフェプリストン
    • VGX-410C

企業のステートメント

事業所および子会社

  • 本社
  • その他の事業所・子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08087CDB

Summary

Global Markets Direct's, 'Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Inovio Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Inovio Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Inovio Pharmaceuticals, Inc.
  • The report provides overview of Inovio Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Inovio Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Inovio Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Inovio Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Inovio Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Inovio Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Inovio Pharmaceuticals, Inc. Snapshot
    • Inovio Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Inovio Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Inovio Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Inovio Pharmaceuticals, Inc. - Pipeline Products Glance
    • Inovio Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Inovio Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Inovio Pharmaceuticals, Inc. - Drug Profiles
    • VGX-3100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-8000
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FVH-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain A/H3N2] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-1400
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-3106
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-3510
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-4212
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-4500
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-5150
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PENNVAX-B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PENNVAX-G
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PENNVAX-GP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VGX-3400X
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VRC-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • chikungunya vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Clostridium difficile vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Ebola Virus Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-5400
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAV-12
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Tyrosinase for Oncology and Immunology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Chikungunya
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • respiratory syncytial virus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RSQ-15
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccines for Neurological Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Inovio Pharmaceuticals, Inc. - Pipeline Analysis
    • Inovio Pharmaceuticals, Inc. - Pipeline Products by Target
    • Inovio Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Inovio Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Inovio Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Inovio Pharmaceuticals, Inc. - Dormant Projects
  • Inovio Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • mifepristone
      • VGX-410C
  • Inovio Pharmaceuticals, Inc. - Company Statement
  • Inovio Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Inovio Pharmaceuticals, Inc., Key Information
  • Inovio Pharmaceuticals, Inc., Key Facts
  • Inovio Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Inovio Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Inovio Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • Inovio Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Inovio Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016
  • Inovio Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Inovio Pharmaceuticals, Inc. - Phase II, 2016
  • Inovio Pharmaceuticals, Inc. - Phase I, 2016
  • Inovio Pharmaceuticals, Inc. - Preclinical, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Inovio Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Inovio Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • Inovio Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016
  • Inovio Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Inovio Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Inovio Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top